142 related articles for article (PubMed ID: 35882652)
1. Prognosis of different extrathoracic metastasis patterns in patients with M1c lung adenocarcinoma receiving immunotherapy.
Hu F; Peng J; Mao X; Niu Y; Ma M; Zhao Y; Gu A; Jiang L
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3171-3184. PubMed ID: 35882652
[TBL] [Abstract][Full Text] [Related]
2. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
Sakai K; Kuramoto J; Kojima A; Nishimura H; Kuwabara Y; Toda M; Kobayashi Y; Kikuchi S; Hirata Y; Mikami-Saito Y; Mikami S; Kyoyama H; Moriyama G; Gemma A; Uematsu K
Int J Clin Oncol; 2019 Dec; 24(12):1549-1557. PubMed ID: 31452019
[TBL] [Abstract][Full Text] [Related]
3. M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.
Park H; Dahlberg SE; Lydon CA; Araki T; Hatabu H; Rabin MS; Johnson BE; Nishino M
Oncologist; 2019 Aug; 24(8):e749-e754. PubMed ID: 30696724
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.
Metzenmacher M; Griesinger F; Hummel HD; Elender C; Schäfer H; de Wit M; Kaiser U; Kern J; Jänicke M; Spring L; Zacharias S; Kaiser-Osterhues A; Groth A; Hipper A; Zaun G; Dörfel S; Güldenzoph B; Müller L; Uhlig J; Thomas M; Sebastian M; Eberhardt WEE;
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36180086
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer.
Tufman A; Kahnert K; Kauffmann-Guerrero D; Manapov F; Milger K; Müller-Lisse U; Winter H; Huber RM; Schneider C
Strahlenther Onkol; 2017 May; 193(5):392-401. PubMed ID: 28246699
[TBL] [Abstract][Full Text] [Related]
6. The TNM 8 M1b and M1c classification for non-small cell lung cancer in a cohort of patients with brain metastases.
Nieder C; Hintz M; Oehlke O; Bilger A; Grosu AL
Clin Transl Oncol; 2017 Sep; 19(9):1141-1146. PubMed ID: 28357633
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer.
Shin J; Keam B; Kim M; Park YS; Kim TM; Kim DW; Kim YW; Heo DS
J Thorac Oncol; 2017 Mar; 12(3):520-528. PubMed ID: 27867003
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Rami-Porta R; Asamura H; Travis WD; Rusch VW
CA Cancer J Clin; 2017 Mar; 67(2):138-155. PubMed ID: 28140453
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of M descriptors of the 8th edition of TNM classification of lung cancer.
Dias M; Antunes A; Campainha S; Conde S; Barroso A
J Thorac Dis; 2017 Mar; 9(3):685-691. PubMed ID: 28449476
[TBL] [Abstract][Full Text] [Related]
11. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
Prelaj A; Lo Russo G; Proto C; Signorelli D; Ferrara R; Galli G; De Toma A; Randon G; Pagani F; Trevisan B; Ganzinelli M; Zilembo N; Montrone M; Longo V; Pesola F; Pizzutilo P; Del Bene G; Varesano N; Galetta D; Torri V; Garassino MC; Di Maio M; Catino A
Clin Lung Cancer; 2020 Sep; 21(5):e337-e348. PubMed ID: 32291212
[TBL] [Abstract][Full Text] [Related]
12. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns.
Hu F; Zhang B; Li C; Xu J; Wang H; Gu P; Zheng X; Nie W; Shen Y; Zhang H; Hu P; Zhang X
J Cancer; 2019; 10(5):1254-1262. PubMed ID: 30854135
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study.
Ma K; Guo Q; Li X
BMC Pulm Med; 2023 May; 23(1):175. PubMed ID: 37208639
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
[TBL] [Abstract][Full Text] [Related]
16. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
[TBL] [Abstract][Full Text] [Related]
18. Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study.
Sun Z; Sui X; Yang F; Wang J
Lung Cancer; 2019 Mar; 129():98-106. PubMed ID: 30545693
[TBL] [Abstract][Full Text] [Related]
19. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
20. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
[Next] [New Search]
